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AbstrACt
Purpose Despite significant progress, challenges remain 
in the management of critically ill children, including early 
identification of infection and organ failure and robust 
early risk stratification to predict poor outcome. The 
Biomarkers of Acute Serious Illness in Children study aims 
to identify genetic and biological pathways underlying 
the development of critical illness in infections and organ 
failure and those leading to poor outcome (death or severe 
disability) in children requiring emergency intensive care.
Participants We recruited a prospective cohort of 
critically ill children undergoing emergency transport to 
four paediatric intensive care units (PICUs) in Southeast 
England between April 2014 and December 2016.
Findings to date During the study period, 1017 
patients were recruited by the regional PICU transport 
team, and blood and urine samples were obtained at/
around first contact with the patient by the transport 
team. Consent for participation in the study was deferred 
until after PICU admission and 674 parents/carers were 
consented. Further samples (blood, urine, stool and 
throat swabs) were collected after consent. Samples 
were processed and stored for genomic, transcriptomic, 
proteomic and metabolomic analyses. Demographic, 
clinical and laboratory data at first contact, during PICU 
stay and at discharge, were collected, as were detailed 
data regarding infectious or non-infectious aetiology. In 
addition, 115 families have completed 12-month validated 
follow-up questionnaires to assess quality of life and 
child behaviour. The first phase of sample analyses 
(transcriptomic profiling) is currently in progress.
Future plans Stored samples will be analysed using 
genomic, proteomic and metabolic profiling. Advanced 
bioinformatics techniques will be used to identify 
biomarkers for early diagnosis of infection, identification of 
organ failure and risk stratification to predict poor outcome 
(death/severe disability).
trial registration number NCT03238040.
IntroduCtIon
Each year, nearly 20 000 children are admitted 
to paediatric intensive care units (PICUs) in 
the UK.1 Considerable progress has been 
made in the understanding of paediatric 
critical illness and how best to provide organ 
support to improve outcomes, and mortality 
for children admitted to intensive care has 
reduced dramatically over the past four 
decades.2 However, significant gaps remain in 
our current knowledge. In particular, short-
term outcomes of emergency admissions 
to PICU remain suboptimal (mortality of 
7%–8%), and relatively little is known about 
longer term morbidity in survivors.3 4
Severe infection is a leading cause of 
life-threatening illness in children. Yet, early 
strengths and limitations of this study
 ► The BASIC study comprises a large cohort of critical-
ly ill children admitted to multiple PICUs in England, 
with biological samples linked to detailed demo-
graphic and clinical data regarding the intensive 
care course as well as 12-month follow up data col-
lected using validated quality of life and behavioural 
questionnaires. 
 ► A careful process of clinical phenotyping has been 
undertaken to classify patients into infectious and 
non-infectious disease aetiologies.  Samples have 
been stored for future proteomic and genomic 
analyses. 
 ► The process of deferred consent meant that se-
verely ill patients recruited to the study who died 
before consent could be obtained, as well as chil-
dren discharged from the PICU before families were 
approached for consent, were excluded, limiting the 
generalisability of our study findings.
 ► We were unable to classify nearly a quarter of the 
patients by their infection aetiology most likely due 
to the use of a clinical definition as the gold standard 
for classification. Although we attempted to collect 
samples from prior to interventions, a significant 
proportion of children had been mechanically ven-
tilated and treated with antibiotics by the time the 
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identification of infection and further discrimination of 
whether it is bacterial (treatable with antibiotics) or viral 
remain a significant challenge in the acute/critical care 
setting.5 6 Consequently, most, if not all, critically ill chil-
dren are started and then remain on broad-spectrum anti-
biotics for several days; prolonged antibiotic use increases 
the risk of side-effects, increases cost and contributes to 
development of antimicrobial resistance.7 8 A second chal-
lenge is that development of organ failure and progres-
sion to irreversible multiple organ failure is the final 
common pathway that leads to death or severe disability 
in children with critical illness, yet current approaches 
are reactive rather than proactive, using clinical and 
biochemical abnormalities to diagnose established organ 
failure rather than identify incipient organ failure.9–11 
Finally, while the future of interventional clinical trials in 
intensive care crucially hinges on early risk stratification, 
current severity of illness scores are  designed for use in 
populations of patients rather than in individuals, and are 
designed to predict mortality, an uncommon and increas-
ingly less relevant outcome of intensive care.12 13
The potential of multiomics technologies in unravelling 
the complex interactions between genes, proteins and 
biochemical reactions in other areas of medicine provides 
a strong indication that in order to fill existing gaps in 
our current knowledge in critical care, a comprehensive 
systems biology approach can be successfully applied to 
the study of large, diverse groups of sick children at an 
early stage of critical illness.14–21 The Biomarkers of Acute 
Serious Illness in Children (BASIC) study is a multicentre 
collaborative study to identify genetic and biological path-
ways underlying the development of critical illness, organ 
failure and poor outcome (death or severe disability) in 
children requiring emergency intensive care.
Cohort desCrIPtIon
study aims
The three key study aims were to: (1) develop a gene 
expression biomarker of bacterial infection which can be 
further developed as a simple point-of-care test to distin-
guish infections from other causes, and bacterial from 
viral infection, in critically ill children; (2) discover and 
validate biomarkers for early accurate detection of single 
and multiple organ failure that can predict organ failure 
earlier than the existing scores which are based on clin-
ical data and laboratory tests that are already deranged; 
(3) identify biomarker-based strategies to help risk stratify 
critically ill children with diverse aetiologies at an early 
stage based on their predicted outcome in intensive care.
study cohort
BASIC is a multicentre, prospective, observational study 
involving a regional PICU transport service and four PICUs 
in southeast England (Great Ormond Street Hospital, 
St Mary’s Hospital and the Royal London Hospital in 
London, and Addenbrookes’ Hospital in Cambridge). 
Eligible patients were critically ill children aged 0–16 
years requiring emergency transfer by the Children’s 
Acute Transport Service (CATS) to a study PICU, with an 
indwelling catheter (arterial and/or central venous cath-
eter for blood sampling and urinary catheter for urine 
sample collection). This simple and practical criterion 
has been shown in previous work to enrich the sample by 
selecting patients at high predicted risk of mortality, the 
median risk of death being 10% in the group of patients 
with an indwelling catheter, as compared with 8% in all 
transported children (as per CATS audit data). Children 
transported to other PICUs or non- PICU destinations, 
premature newborns (under 36-week corrected gesta-
tional age) and those with a known do-not-attempt-resus-
citation order in place were excluded.
Patient recruitment and informed consent
All transported children were screened for eligibility by 
medical and nursing staff from the CATS team at first face-
to-face patient contact. Eligible patients were recruited to 
the study and blood±urine samples were collected from 
indwelling catheters, coinciding with routine clinical 
sampling. Ethical approval was granted for consent to be 
deferred (also known as ‘research without prior consent’) 
due to the emergency setting, similar to previous clinical 
trials in paediatric emergency care; deferred consent has 
been shown to be acceptable to clinicians as well as partic-
ipants.22–24 A written informed consent was obtained by 
the research team in the admitting PICU from parents/
guardians once the child’s condition had stabilised, 
usually within 24–48 hours following PICU admission. As 
per ethical approval provided for deferred consent in our 
study, carers of children who died prior to approach for 
consent were excluded from the study. Parents/guardians 
could consent for full participation in the study (analysis 
of samples and clinical data already collected, further 
sample collection on the day of consent and data collec-
tion until the child’s discharge from PICU, and contact 
to complete follow-up questionnaires at 12 months after 
PICU admission, if appropriate) or partial participation 
(analysis of samples and clinical data already collected 
but no further involvement), or refuse consent (samples 
and clinical data already collected to be discarded).
sample collection
Sample collection and transport procedures were 
devised based on previous work, the UK Biobank oper-
ating procedures and information from related sample 
handling validation studies (see table 1).25 26 Blood and 
urine samples were collected at two points of time: during 
transport to PICU (time point 1) and after consent was 
obtained (time point 2). Time point 1 samples were trans-
ported on ice packs (4°C) to the admitting PICU where 
they were processed by the local research team. Samples 
were anonymised by means of a unique study number 
assigned by the CATS team to each recruited patient. 
Processed samples were stored at −80°C at individual sites 
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Clinical data
A standardised case report form and data collection 
manual with definitions and rules were produced for 
research staff at each PICU. Clinical data collected 
covered the key stages of the patient’s pathway—intensive 
care referral and transport, PICU course and outcome. 
As shown in the online supplementary table 1 and in 
tables 2–4, detailed clinical phenotyping information was 
collected, including reason for PICU referral/admission 
(infection, trauma, neurological, cardiac, respiratory and 
other), severity of illness (Paediatric Index of Mortality 
2, PIMS-2 score), severity of organ failure (PEdiatric 
Logistic Organ Dysfunction, PELOD-2 score) on days 0, 
1, 2 and 3, and outcome at discharge from PICU (death, 
severe disability). In addition, we used screening ques-
tions regarding general health and functional status and 
validated age- questionnaires (Child Behaviour Checklist 
and Pediatric Quality of Life Inventory, PedsQL) to assess 
the child’s adaptive behaviour, general quality of life and 




1. Diagnosis of bacterial infection by laboratory tests (cul-
ture, molecular diagnostics) within the first 28 days or 
prior to PICU discharge.
2. Multiorgan failure—failure of two or more organs us-
ing the PELOD-2 score within the first 28 days or prior 
to PICU discharge.
3. Poor outcome defined as mortality or development of 
a new severe disability at intensive care unit discharge.
Secondary
1. Long-term health-related quality of life assessed at 12 
months by the age-appropriate PedsQL questionnaire 
completed by parent proxy.
2. Long-term behavioural outcome assessed at 12 months 
by the age-appropriate Child Behaviour Checklist com-
pleted by parent proxy.
sample size
No formal sample size calculations were performed, but 
we aimed to recruit adequate numbers of patients with 
different reasons for intensive care admission as well as 
those experiencing the primary outcomes (50–80 patients 
per group of interest). According to previous audit data, 
we estimated that we could recruit up to 800 patients over 
the study period.
sample analyses
In the first phase of sample analyses, we will address the 
first key study aim, namely the development of a gene 
expression biomarker to distinguish infections from 
other causes, and bacterial from viral infection. We will 
not limit our analyses to a preselected list of biomarkers, 
instead a hypothesis-free approach will be pursued. 
Whole blood was collected in PAXgene blood RNA tubes 
(PreAnalytiX), and later extracted using PAXgene blood 
RNA kits (PreAnalytiX). RNA was shipped to the Oxford 
Genomics Center for analysis on HumanHT-12 V.4 
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expression Beadarrays (Illumina). Other samples will be 
stored for future analyses, and in further phases, we will 
consider the use of genomics, rapid throughput proton 
nuclear magnetic resonance spectroscopy and mass 
spectrometry techniques to explore the role of protein 
biomarkers, as well as undertaking metabolomic analyses. 
DNA will be used for genotyping of genes implicated in 
sepsis or critical illness, enabling linking of genetic and 
transcriptomic information.
study organisation
The study was conducted under the leadership of a BASIC 
study management group comprising the investigators 
with overall responsibility for protocol design, study 
conduct and publication. Imperial College serves as the 
coordinating centre for sample and informatics analyses.
FIndIngs
During the study period of 33 months (1 April 2014–7 
December 2016), 2333 children were transported to 
the participating PICUs by the CATS team. As shown 
in figure 1, although 1054 patients were recruited to 
the BASIC study by the CATS team, 37 were ineligible 
since they were not eventually admitted to a study PICU. 
Consent for participation was obtained from parents/
guardians of 674 children (66.1% of the 1017 children 
admitted to a study PICU). The main reason for not 
obtaining consent from patients was death or discharge 
of the patient from the PICU prior to being approached 
by the research team (137/1017, 13.5%). Parents/guard-
ians refused consent in 114/1017 (11.2%).
Cohort characteristics are shown in table 2. An overview 
of samples and time points at which collected, processing 
and storage instructions, and total numbers of samples 
stored is summarised in table 1.
Details regarding the PICU stay and short-term 
outcomes for the children enrolled are shown in Table 3.
At the end of the PICU stay, study patients were classi-
fied into one of six groups based on their infection status 
as a reason for admission (non-infectious condition; defi-
nite bacterial, definite viral, probable bacterial and prob-
able viral infections; and unable to determine infection 
status) as shown in table 4.
We used an algorithm as described previously to 
perform this classification (online supplementary figure 
1).27 The classification was performed by two investigators 
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(JCW and YF) and a random sample of 10% of records 
was checked by one investigator (PR). Any queries arising 
during this classification were resolved by discussion with 
PR.
Patient and public involvement
Parents of children previously transported to an inten-
sive care unit were involved in the pilot testing of the 
12-month follow-up questionnaires and provided input 
into the choice of the questionnaires. Although there was 
no formal involvement of parents/public in the develop-
ment of the research question and outcome measures 
chosen, clinicians within the research team identified the 
research question and outcomes as being important for 
patients from informal discussions with patients/parents.
strengths and limitations
The BASIC study comprises a large cohort of critically ill 
children admitted to multiple PICUs in England, with 
biological samples linked to detailed demographic and 
clinical data regarding the intensive care course as well 
as 12-month follow-up data collected using validated 
quality of life and behavioural questionnaires. A careful 
process of clinical phenotyping has been undertaken 
to classify patients into infectious and non-infectious 
disease aetiologies. Samples have been stored for future 
proteomic and genomic analyses.
recruitment in an emergency setting
One of the unique strengths of this cohort is the 
timing and extensive nature of sample and clinical data 
Table 2 Demographic and clinical characteristics of cohort 
(n=674)
Variable n (%)
Male gender 367 (54.5)
13 (1.9)
Ethnicity
  Asian 77 (11.4)
  Black 53 (7.9)
  White 312 (46.3)
  Other 40 (5.9)
  Missing 192 (28.5)
Age group
  0–1 month 112 (16.6)
  1–11 months 148 (22)
  1–4 years 212 (31.5)
  5–12 years 132 (19.6)
  >12 years 55 (8.2)
  Missing 15 (2.2)
Consanguinity 22 (3.3)
  Missing 203 (30.1)
Comorbidities present 342 (51)
  Missing 42 (6.2)
Comorbidities*
  Respiratory 110 (16.3)
  Cardiac 73 (10.8)
  Neurological 134 (19.9)
  Genetic/syndrome 62 (9.2)
  Metabolic/endocrine 33 (4.9)
  Haematological/oncological 13 (1.9)
  Multisystem disorder 8 (1.2)
  Other 103 (15.3)
Gestational age, median (IQR)† 38 (36–40) (n=245)
Time from onset of symptoms to first contact with transport 
team
  Less than 6 hours 126 (18.7)
  6–24 hours 169 (25.1)
  24–72 hours 168 (24.9)
  3–7 days 123 (18.2)
  >7 days 73 (10.8)
  Missing 15 (2.2)
PCPC status (prior to PICU admission)
  Normal 434 (64.4)
  Mild disability 38 (5.6)
  Moderate disability 52 (7.7)
  Severe disability 64 (9.2)
  Missing 86 (12.8)
POPC status (prior to PICU admission)
  Normal 433 (64.2)
Continued
Variable n (%)
  Mild disability 38 (5.6)
  Moderate disability 57 (8.5)
  Severe disability 62 (9.2)
  Missing 84 (12.5)
Acuity during transport to PICU
  Invasively ventilated 573 (85)
  Inhaled nitric oxide 25 (3.7)
  Received>40 mL/kg fluid bolus 51 (7.6)
  Vasoactive agents 260 (38.6)
  Blood product transfusion 13 (1.9)
  Maximum vasoactive-inotropic 
score, median (IQR)
20 (10–65) (n=243)
Fixed and dilated pupils 6 (0.9)
PELOD-2 score, median (IQR) 6 (4–8) (n=674)
PIM-2 mortality risk, median (IQR) 3.8% (1.4–5.3) (n=674)
*Same child may have comorbidities of different groups.
†Gestational age was collected only for children<2-year old.
PCPC, paediatric cerebral performance category; PELOD-2, 
PEdiatric Logistic Organ Dysfunction; PICU, paediatric 
intensive care unit; PIM-2, Paediatric Index of Mortality—2; 
POPC, paediatric overall performance category.
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collection in a population of critically ill children. In 
contrast to similar previous cohorts, we chose to stan-
dardise the timing of sample collection to the point 
of first contact with an intensive care team early in the 
course of critical illness, rather than after PICU admis-
sion. This provides the opportunity to collect biological 
samples at the earliest time point as practically possible 
during critical illness, when the confounding effect of 
a dynamically evolving pathophysiology and the influ-
ence of critical care interventions such as mechanical 
ventilation and vasoactive agent treatment may be 
ameliorated. In addition, even though patients may 
first present to hospitals at various stages of their crit-
ical illness, by standardising sample collection to the 
earliest possible time point, we attempted to generate a 
more homogenous cohort than possible if patients were 
recruited at various time points after PICU admission.
Consent model
Recognising that asking parents/guardians to consent 
to a research study in a busy emergency setting (where 
the priority for the transport team is to perform life-
saving interventions) may result in a less than ideal 
informed consent process, we chose to defer written 
consent until after PICU admission, when the child’s 
clinical condition had stabilised. We provided parents 
Table 3 Course during intensive care stay (N=674)
Variable n (%)
Type of admission
  Unplanned, after surgery 19 (2.8)
  Unplanned, other 650 (96.5)
  Missing 5 (0.7)












Number of hours on ECLS, mean (SD) 3.93 (30.07) 
(n=15)
Number of hours on CRRT, mean (SD) 2.6 (26.87) 
(n=12)
Abnormal brain imaging 116 (17.2)
  Missing 10 (1.5)
Abnormal neurophysiology 99 (14.7)
  Missing 7 (1.0)
Cardiac arrest during this admission 12 (1.8)
  Missing 7 (1.0)
PICU discharge status
  Died 27 (4.0)
  Alive 636 (96)
  Missing 11 (1.6)
Discharge location
  Home 18 (2.7)
  Hospice 5 (0.7)
  Other 10 (1.5)
  Other hospital 312 (46.3)
  Same hospital 291 (43.2)
  Missing 37 (5.6)
Discharge POPC
  Normal 358 (53.1)
  Mild disability 54 (8)
  Moderate disability 46 (6.8)
  Severe disability 70 (10.4)
  Coma/vegetative state 1 (0.1)
  Missing 145 (21.5)
Discharge PCPC
  Normal 363 (53.9)
  Mild disability 54 (8)
  Moderate disability 41 (6.1)
  Severe disability 69 (10.2)
  Coma/vegetative state 1 (0.1)
  Brain death 1 (0.1)
  Missing 145 (21.5)
Continued
Variable n (%)
Ventilator free days at day 30, median (IQR) 25 (22–27) 
(n=642)
PICU free days at day 30, median (IQR) 24 (19–26) 
(n=642)
PCPC, paediatric cerebral performance category; PICU, 
paediatric intensive care unit; POPC, paediatric overall 
performance category.
Table 3 Continued 
Table 4 Classification of reasons for paediatric intensive 
care unit admission (n=669)
Classification n (%)
Definite bacterial infection 61 (9.1)
Definite viral infection 146 (22)
Probable bacterial infection 60 (8.9)
Probable viral infection 27 (4.0)
Inconclusive for bacterial or viral infection 159 (23.6)
Non-infectious condition 215 (31.9)
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with the option for either full or partial participation 
in the study, or for refusal of consent. Although we saw 
a low proportion of refusal of consent (~10%), prac-
tical challenges of providing 7 days a week research 
nurse cover on the units to approach recruited partic-
ipants meant that a significant proportion were not 
approached for consent resulting in collected samples 
being destroyed.
Limitations
The process of deferred consent resulted in bias: 31 
children who were recruited to the study died before 
consent could be obtained from families, which, as per 
approved ethical procedures, resulted in their exclu-
sion from the study. Due to this exclusion, severely 
ill patients were excluded limiting the generalisability 
of our study findings. Similarly, 70 children were 
recruited to the study but were discharged from the 
PICU before families were approached for consent, 
resulting in their exclusion. Despite the high level of 
detail contained in the clinical database, we found 
that four patients were excluded due to missing data 
on key data such as their outcome and infection status. 
In addition, we were unable to classify nearly a quarter 
of the patients by their infection aetiology most likely 
due to the use of a clinical definition as the gold 
standard for classification. Although we attempted to 
collect samples from prior to interventions, a signif-
icant proportion of children had been mechanically 
ventilated and treated with antibiotics by the time the 
transport team arrived at the local hospital.
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